WhatsApp Channel Join Now
Telegram Group Join Now

Relevance: GS Paper III — Science & Technology (Biotechnology, Health) Source: ASCO Annual Meeting 2026 / NEJM

1 · What happened

At the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 (Chicago), results of the Phase 3 RASolute 302 trial showed that an experimental oral pill, Daraxonrasib, nearly doubled survival in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose cancer had progressed after first-line treatment.

Median overall survival rose to 13.2 months on Daraxonrasib versus 6.7 months on standard chemotherapy. The drug also had a milder side-effect profile (rash, oral ulcers, vomiting). Findings were published in The New England Journal of Medicine (NEJM). Pancreatic cancer is one of the deadliest cancers worldwide — survival had improved only marginally over three decades.

2 · How the drug works — and why this is a paradigm shift

RAS gene logic: RAS is a protein switch inside cells that controls growth signals. Mutated RAS gets stuck in the “ON” state, driving uncontrolled cell division. Daraxonrasib is a multi-selective RAS(ON) inhibitor that blocks this stuck-on state from inside the cell.

The Drug & Trial
Daraxonrasib (RASolute 302)
An oral, multi-selective RAS(ON) inhibitor by Revolution Medicines. First RAS inhibitor in a large randomised pancreatic-cancer trial. Benefit seen in both RAS-mutant and RAS-wild-type tumours.
The Future of Treatment
Precision oncology
Treatments tailored to a tumour’s genetic profile. Daraxonrasib will work alongside surgery, chemotherapy and radiotherapy, not replace them — a multi-modal personalised regimen.
The Crucial Mechanism
KRAS — the master switch
KRAS is the most common RAS gene. KRAS mutations appear in ~20% of all cancers but in ~80% of pancreatic cancers — making the pancreas the perfect testbed for RAS-targeted therapy.
Why Pancreatic Cancer is Deadly
Late detection + dense stroma
70–90% of cases are caught at an advanced stage. The tumour’s surrounding tissue (stroma) blocks drugs from reaching cancer cells. 5-year survival in metastatic disease ≈ 3%.

  • India profile: ~23,000 new cases per year; crude incidence rate 1.6 per 100,000. Ranks 24th in cancer incidence but 18th in cancer mortality — the deadliness gap.
  • India-specific risk: rising diabetes, obesity, alcohol use, and tropical pancreatitis (prevalent in Kerala and Tamil Nadu).
  • Wider use: Daraxonrasib is being evaluated for lung and colon cancers, where RAS mutations are also common — a possible cross-organ targeted therapy.

UPSC Value Box
Daraxonrasib Oral, multi-selective RAS(ON) inhibitor (Revolution Medicines). The first RAS-targeting drug to show a major survival gain in a Phase 3 pancreatic-cancer trial.
RAS / KRAS gene RAS encodes proteins that switch cell-growth signals on/off. KRAS is the most common variant; mutations leave the switch jammed “ON”, driving cancer.
Pancreatic Ductal Adenocarcinoma (PDAC) The most common form of pancreatic cancer, arising from cells lining the pancreatic ducts. Notoriously aggressive and detected late.
Tumour Stroma The dense connective tissue surrounding a tumour. In pancreatic cancer, it forms a physical and chemical barrier that blocks drugs from reaching the cancer cells.
Precision / Personalised Medicine Tailoring treatment to an individual’s genetic, environmental and lifestyle profile — a key plank of National Health Policy 2017 and the Department of Biotechnology’s Genome India initiative.
Tropical Pancreatitis A chronic non-alcoholic form of pancreatitis common in tropical regions, especially Kerala and Tamil Nadu; linked to malnutrition and dietary toxins; raises long-term cancer risk.
ASCO American Society of Clinical Oncology — leading global professional body for oncology; its annual meeting is the most-watched forum for new cancer drug results.

MCQ Practice Question
Q. With reference to Daraxonrasib, recently in the news, consider the following statements:

  1. It is an orally administered RAS(ON) inhibitor that demonstrated a survival benefit in patients with both RAS-mutant and RAS-wild-type metastatic pancreatic cancer.
  2. KRAS mutations are found in approximately 80% of all cancers, while pancreatic cancers account for only a small share of cases harbouring such mutations.
  3. The drug’s Phase 3 trial results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

Which of the statements given above is/are correct?
(a) 1 and 2 only    (b) 2 and 3 only    (c) 1 and 3 only    (d) 1, 2 and 3

Answer: (c) 1 and 3 only

  • Statement 1 — Correct: Daraxonrasib is an oral, multi-selective RAS(ON) inhibitor. The RASolute 302 trial showed a survival benefit regardless of RAS mutation status — including RAS-wild-type tumours — a striking departure from earlier mutation-specific drugs.
  • Statement 2 — Incorrect (the trap): The numbers are swapped. KRAS mutations are found in ~20% of all cancers, but in ~80% of pancreatic cancers. Pancreatic cancer is therefore the most KRAS-driven tumour, which is exactly why it is the prime testbed for RAS-targeting drugs — the very opposite of what the statement claims.
  • Statement 3 — Correct: The Phase 3 results were presented at the ASCO Annual Meeting 2026 in Chicago and published simultaneously in The New England Journal of Medicine.

Share This Story, Choose Your Platform!

Ajmal IAS APSC Foundation Course

Recent Posts

Ajmal IAS APSC Foundation BATCH
Ajmal IAS APSC Foundation Course

Start Yours at Ajmal IAS – with Mentorship StrategyDisciplineClarityResults that Drives Success

Your dream deserves this moment — begin it here.